6 tumour histologically and 9 of these survived five years (7 tumour free at over six years). Four had positive nodes and 3 of these survived five years (1 tumour free at six years).
Group 2: Of 14 patients with localized recurrence treated by excision and grafting plus perfusion, 11 survived over five years. Negative inguinal or axillary nodes were found in 9 patients, all of whom survived five years; 1 patient had 2 perfusions. Of the 5 patients with positive nodes, 2 survived five years.
Group 3: Of 13 patients treated with perfusion alone, 7 lived five years, 4 of whom had more than one perfusion. Of the remaining 6 patients, 4 had a short response and 2 had no response.
Discussion
These results compare well with those of Heise et al. (1961) who, in a five-year survey of 1447 patients with limb melanoma who had undergone all forms of treatment, reported an overall survival of 51.5 %. McBride & Clark (1971) , reviewing 240 patients following perfusion, concluded that there was a 10% increase in five-year survival compared with conventional treatment; local recurrence, skin grafting and amputation were also reduced. Krementz & Ryan (1972) , reporting 14 years experience with perfusion for invasive limb melanoma, showed that of 108 patients with Stage 1 melanoma, 87 were disease free at five years, and of the 119 patients with Stage 2 melanoma, 50 were disease free at five years.
Conclusion
Although this series is small the following points can be made. Regional perfusion for melanoma is a relatively safe procedure in suitable centres, there was no loss of limbs and no deaths in this series. Our results, supported with other series, indicate that regional perfusion probably does offer patients increased survival to five years with a long tumour-free interval. Patients with extensive limb melanoma which could be excised and grafted at the expense of lympheedema and possible ulceration with severe cellulitis often have a response to perfusion, like those patients with inoperable limb disease, which may be prolonged. Amputation in this situation may be avoided. Treatment of malignant melanomas by chemotherapy is unsatisfactory. Even with the best drugs, used as single agents, some 80% of patients show no response. Such successes as have been claimed, most in non-randomized, uncontrolled clinical evaluation studies, have to be judged against the very variable clinical course that this malignancy may take. Even without treatment, some nodules may regress, whilst other nodules grow vigorously. The published literature therefore probably reflects a response rate which errs on the optimistic (Table 1) . Studies in which few or no objective regressions are obtained are also less likely to be reported.
Actinomycin D is claimed to give an objective response rate of 33 %; though it must be asked at what toxic cost, how long were regressions maintained, how complete were they and how much clinical benefit did patients obtain. In any tabulation of anticancer drugs the answers to these questions ought to be built into their ranking.
It seems curious that so few cases treated with cyclophosphamide, an agent about which so much is known, have been reported; particularly as it appears to have given reasonable results. If one can judge from the few cases that have been reported, low doses (7.5 mg/kg i.v. per day for 6 days and then 10 mg/kg per week) are as effective as high single doses of 100 mg/kg i.v. repeated every three weeks. DTIC or 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide has been very widely tested in the last three years, particularly in the United States. It appears to be an antimetabolite competitive with 5-aminoimmidazole-4-carboxamide, a precursor in de novo synthesis of purine. In addition, it also behaves as an alkylating agent. Its exact mechanism of action is uncertain.
There is a striking consistency of approximately 20% in the response rate, in individual reports (Carter & Friedman 1972) . This is somewhat unusual, but probably indicates a true and direct activity on the tumour. Where responses are very variable, as for example those given for actinomycin D and hydroxyurea where responses have been as low as zero, it is probable that variable blood levels may be as much responsible as variable responses by the melanoma cells to the drug involved.
Because of erratic oral absorption (Loo et al. 1968 ) DTIC can only be given intravenously. Adapted from Carter & Friedman (1972) Dosages of 250 mg/m2 i.v. per day for 5 days repeated every three weeks and 4.5 mg/kg i.v. per day for 10 days repeated every four weeks have been studied, but the results appear to be much the same. The lower dose therefore seems preferable. Toxicity encountered has involved chiefly the gastrointestinal tract and bone marrow. Anorexia, nausea and vomiting affects nearly all patients. The vomiting may last up to 12 hours and may be difficult to control by sedatives. These symptoms may only be seen with the first few doses and are worst during the first hour after administration of the drug. Although bone marrow suppression is usually completely reversed 1 month after start of treatment some fatalities have occurred. It is therefore necessary to proceed with care, since 'idiosyncratic' bone marrow responses may lead to severe leukopenia and thrombocytopenia.
Attempts are now being made to improve the results with DTIC by the study of analogues and by combination chemotherapy involving DTIC.
Combinations of antitumour agents are generally more effective than one might have anticipated. This is partly because the toxicities do not seem to be additive to the same degree as the antitumour effects and partly because by appropriate time and sequence of administration (often fortuitous) of the individual drugs of the combination a much greater tumour cell kill is possible. This is related, albeit very imperfectly, to differences in cell sensitivities to drugs at various stages of the cell cycle. Tannock & Frei (1971) used a combination of vincristine (cycle active), bis-chloroethyl nitrosourea (cycle independent) and DTIC (cycle active and independent) and in a preliminary study obtained 40 % objective responses in patients with metastatic melanoma.
A sensitive index of active malignant melanoma would obviously be of the greatest value. Crawhall et al. (1966) studied the significance of melanogenuria. Although it decreased witla successful use of anticancer drugs, it was unfortunately not evident until the disease was far advanced.
The following paper was also read: The basic event in malignant change may be thought of either as a change occurring in a single cell whose progeny are all potentially malignant cells or alternatively as a change occurring in a whole field of cells whose progeny are not themselves malignant but which behave in such a way that the selection, perhaps by a series of events, of one or more malignant cell lines from amongst them is more probable than from among normal cells.
One of the primary features of tumour cells is their variability. Variation in the morphology of the nuclei of tumour cells is a feature of most histological sections of tumour tissue and this is a reflection of wide variations in the chromosome content. With the exception of the Philadelphia chromosome in chronic myeloid leukaemia no constant abnormality is seen in tumours of the same histological type although there are reports
